PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2013
CASE
AUTH/2644/10/13 Galen

AUTH/2644/10/13: Norgine v Galen β€” Prescribing policy for Laxido Orange (no breach; switch services allegation)

Norgine alleged Galen’s prescribing policy on switching Movicol to Laxido Orange indirectly facilitated a prohibited switch programme. Panel and Appeal Board ruled…

2015
CASE
AUTH/2793/9/15 AstraZeneca

AstraZeneca Forxiga EMIS Web β€˜9 step guide’ ruled misleading; corrective statement and public reprimand (AUTH/2793/9/15)

AstraZeneca’s EMIS Web search guide for identifying patients for Forxiga was ruled misleading and inconsistent with the SPC, with undue weight-loss emphasis…

2015
CASE
Actavis ⭐ Case of the Week

Bayer v Actavis: Levosert leavepiece ruled misleading on breadth of suitability and β€œ25% saving” cost claim

Actavis’ Levosert leavepiece implied broader suitability than Mirena and claimed a β€œ25% saving” on acquisition cost. PMCPA ruled the claims misleading/unsubstantiated and…

2015
CASE
AUTH/2756/5/15 Merck Serono

Merck Serono call-rate targets: pressure for β€œ6 calls/contacts per day” and uncertified field briefings (AUTH/2756/5/15)

Anonymous employee alleged Merck Serono neurology KAMs were pushed to achieve 6 calls/contacts per day. Panel found targets risked inconvenience and Code…

2013
CASE
AUTH/2620/7/13 Sanofi

Sanofi breached an undertaking over a repeat β€œonly once-daily GLP‑1RA” claim in a Nursing Times supplement (AUTH/2620/7/13)

Sanofi was found to have breached a prior PMCPA undertaking after a Nursing Times promotional supplement repeated a very similar β€œonly once-daily…

2014
CASE
AUTH/2725/7/14 Roche Products

AUTH/2725/7/14: Member of the public v Roche – Daily Mirror article about Avastin (No breach)

Complaint alleged Roche instigated a Daily Mirror story promoting off-label Avastin use for brain tumours. Panel found allegations not proven on balance…

2014
CASE
AUTH/2716/5/14 Napp Pharmaceuticals

AUTH/2716/5/14: Napp voluntary admissionβ€”conference sponsorship emails implied inducement

Napp admitted concerns about a rep’s conduct. Panel found no breach on alleged false pretence for an appointment, but ruled breaches where…

2013
CASE
AUTH/2666/11/13 Sanofi ⭐ Case of the Week

AUTH/2666/11/13: Member of the public v Sanofi β€” Clinical trial disclosure for Multaq and Jevtana (No breach)

Public complaint alleged Sanofi failed to disclose clinical trial results for Multaq and Jevtana in line with ABPI/IFPMA requirements. Panel reviewed UK-involvement…

2008
CASE
Merck Sharp & Dohme

MSD/Schering-Plough Ezetrol insert in The Pharmaceutical Journal: cholesterol target claim ruled misleading (Clauses 7.2, 7.4, 7.10)

A promotional insert summarising NICE guidance for ezetimibe included a broad claim that 35% of UK CHD patients miss cholesterol targets. The…

2016
CASE
AUTH/2820/2/16 Hospira

Hospira: UK pharmacists taken to Croatia for β€˜advisory board’/site visitβ€”Panel found overseas promotional meeting, inappropriate venue and poor governance (AUTH/2820/2/16)

Media complaint after Telegraph article. PMCPA ruled Hospira’s Croatia site visit/advisory board was not a genuine advisory board, lacked UK certification and…

2016
CASE
AUTH/2854/7/16 Boehringer Ingelheim

AUTH/2854/7/16: Boehringer Ingelheim voluntary admissionβ€”printed promotional materials not re-certified against approved electronic version

Boehringer Ingelheim found 103/~275 hard-copy promotional job bags lacked the required final signatory check that printed items matched the certified electronic version.…

2016
CASE
AUTH/2921/12/16 GrΓΌnenthal

AUTH/2921/12/16: GrΓΌnenthalβ€”Internal Palexia SR video uploaded to YouTube (promotion to the public)

GrΓΌnenthal admitted Code breaches after an internal Palexia SR video was uploaded to YouTube by a third party. The Panel ruled public…

2016
CASE
AUTH/2866/8/16 AstraZeneca ⭐ Case of the Week

AUTH/2866/8/16: Anonymous (non-contactable) v AstraZeneca – engagement of a consultant and training/consultancy company

Anonymous complaint alleged coercive, industry-funded audits/workshops linked to prescribing. Most allegations not proven, but AstraZeneca was found in breach of Clause 9.1…

2016
CASE
AUTH/2922/12/16 Meda Pharmaceuticals

AUTH/2922/12/16: Assistant Director Medicines Management v Meda β€” rep criticised for omitting local β€˜grey list’ status when detailing Dymista

At a GP meeting, a Meda rep detailed Dymista without proactively stating it was locally β€˜grey listed’. PMCPA found the omission misleading…

2017
CASE
AUTH/2942/2/17 Boehringer Ingelheim

AUTH/2942/2/17: Online Spiolto banner ad (Pulse Today) – no breach (Boehringer Ingelheim)

Complaint about an online Spiolto COPD ad: missing generic name for Spiriva, unclear comparator device, and missing/outdated PI and references. Panel found…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training